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& Abstract
Background: Epidural corticosteroid injections are used
frequently worldwide in the treatment of radicular pain.
Concerns have arisen involving rare major neurologic injuries
after this treatment. Recommendations to prevent these
complications have been published, but local implementa-
tion is not always feasible due to local circumstances,
necessitating local recommendations based on literature
review.
Methods: A work group of 4 stakeholder pain societies in
Belgium, The Netherlands, and Luxembourg (Benelux) has
reviewed the literature involving neurological complications
after epidural corticosteroid injections and possible safety
measures to prevent these major neurologic injuries.
Results: Twenty-six considerations and recommendations
were selected by the work group. These involve the use of
imaging, injection equipment particulate and nonparticulate
corticosteroids, epidural approach, and maximal volume to
be injected.
Conclusion: Raising awareness about possible neurological
complications and adoption of safety measures recom-
mended by the work group aim at reducing the risks for
these devastating events. &
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INTRODUCTION
Purpose
Epidural corticosteroid injections (ESIs) are used fre-
quently worldwide for their symptomatic effect.1
Reports of complications published in the past decade
involving the use of epidural corticosteroids led the U.S.
Food and Drug Administration (FDA) in April 2014 to
request that an additional warning be added for the
epidural use of corticosteroids in the prescribing infor-
mation of all available corticosteroids, including non-
particulate steroids. This was confirmed in a publication
in the New England Journal of Medicine.2 In this
warning, it was emphasized that epidural injections of
steroids may cause spinal cord infarction, paraplegia,
quadriplegia, cortical blindness, and stroke.
Furthermore, the epidural administration of corticos-
teroids has not officially been approved by the FDA or
the European Medicines Agency (EMA),2 which means
that it is classified as “off-label” use. The latter reflects
the current clinical practice3 but is also a challenge since
the effectiveness of treatment must be weighed against
the risk for complications.
The FDA’s “Safe Use Initiative” aided in convening a
group of experts on ESIs and led to the publication of a
consensus paper of 13 stakeholder societies.3 In this
consensus, dexamethasone was given a prominent place
for transforaminal (TF) epidural injections; however,
this product is only distributed in the Benelux Union by
1 compounding pharmacy, and the long-term safety of
this product is not known.4 The simple implementation
of these U.S. guidelines was therefore not feasible and
necessitated the organization of a local task force to
review the literature. The Benelux work group reviewed
the literature on complications of ESIs to provide an
updated and practical set of safety recommendations
regarding the use of ESIs.
METHODS
To identify the potential complications of epidural
corticosteroid administration, a literature search was
conducted in January 2016 using the search strategy on
abstract words [Steroid] or [Corticosteroid] and [Epidu-
ral] and [Complications]. The 148 titles and abstracts
retrieved were reviewed by the senior author (K.V.B.) to
define the type of complications that needed further
evaluation and to identify the papers to be used for this
review.
The research questions were divided among the
authors, who each performed a review and formulated
a response. After compilation of the responses, the
members of the work group commented on the complete
paper. Once a consensus was obtained in the work
group, the manuscript was reviewed by the board of the
different pain societies (World Institute of Pain Benelux
section, Nederlandse Vereniging Anesthesiologie section
pain medicine, Vlaamse Anesthesiologische Vereniging
voor Pijnbestrijding, Belgian Pain Society). The com-
ments were incorporated, and the final version was then
validated by the board of the different pain societies.
Complications After Epidural Corticosteroids:
Overview
Physiological Effects. Bone demineralization – There is
uncertainty about the dose of corticosteroids above
which clinically significant bone loss and increased risk
for fracture occurs. However, doses as low as 2.5 mg
prednisone may be enough.5 The number of fractures
doubles even with oral or intermittent administration,
such as an ESI.6 A group of postmenopausal women
sensitive to bone loss who received an epidural injection
of triamcinolone 80 mg were followed prospectively. A
reduction in the mineral bone density of the hip and an
increase in serum markers for bone turnover were
observed at a 6-fold increase compared to the average
annual bone loss in a matched control group.7 Retro-
spective studies confirm that postmenopausal women
who are given multiple ESIs have a lower mineral bone
density score when they receive higher doses of corti-
costeroids (cumulative dose of triamcinolone
>200 mg).8 A large retrospective cohort study compared
the data of 3,000 patients with spinal pain who received
a lumbar ESI with the data of 3,000 matched controls
who did not receive injections. Each ESI increased the
fracture risk by 31%.9 It is therefore recommended to
keep the corticosteroid exposure to a minimum,
particularly for high-risk patients such as the elderly
and women with a prior history of osteoporosis or
osteopenia.10
Suppression of the hypothalamic-pituitary-adrenal
(HPA) axis – An ESI can cause Cushing’s syndrome. In
exceptional cases the HPA axis can still be suppressed 6
to 8 months after the injection.11,12 HPA axis
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suppression without Cushing’s syndrome occurs
frequently and can continue for 3 to 6 weeks.13,14
Immune system – Corticosteroids can cause a dose-
dependent suppression of the immune system that arises
as a result of the transcriptional changes that suppress
the inflammatory genes, upregulate the anti-inflamma-
tory genes, and inhibit B and C cell phagocytes.15 There
are no retrospective studies on rates of infection
following ESI, but case reports have shown that, after
ESI, an infection can occur in patients with existing
immunosuppressive conditions, such as diabetes, cancer
(with and without metastases), and neutropenia, and in
patients taking oral corticosteroids, with a history of
infections,16 and with renal failure.17
Glucose values – Immediately following ESI, elevated
glucose levels can be seen in diabetes patients (insulin-
dependent and non-insulin-dependent)18; elevated glu-
cose levels may persist for two19 to six20 days after the
injection. Patients with diabetes must be given informa-
tion on hyperglycemia after the injection and under-
stand the possible need to adjust their diet and/or their
diabetic treatment.10
Minor Complications. Minor complications are com-
plications without permanent damage that may occur
after caudal, interlaminar, or TF administration in the
lumbar region or after interlaminar cervical corticos-
teroid administration. There is no information available
on thoracic interlaminar or cervical TF injections.21
Table 1 summarizes the types of complications and their
incidence.
Other minor complications after cervical interlami-
nar ESIs22 are axial neck pain, neck pain not position
related, flushing in the face, nausea and vomiting, fever
the night after the intervention (0.3%), sensitivity at the
injection site, a hypotensive episode, respiratory
insufficiency,23 subjective weakness in the arms for
24 hours, and insomnia.
When using the “loss of resistance” technique,
accidental dural puncture may result in pneumocephalus
(air injected in the subarachnoid space that rises to the
brain), as described in 8 cases.24 This type of headache is
different from postdural puncture headache because it
results in an immediate headache, is not related to a
certain position, and is sometimes coupled with neuro-
logical symptoms.25
Flushing can arise during both interlaminar and TF
injections as a result of immunoglobulin E–mediated
mechanisms. The reported incidence varies from 0.1%
to 11%.26 This can be prevented by the prophylactic
administration of an antihistamine.
Persistent hiccup, probably due to the stimulation of
the afferent hiccup reflex curve of the phrenic nerve,
vagal nerve, or sympathetic nerves of T6–T12, disap-
pears with conservative measures or chlorpromazine.27
Intradiscal injections – Unwanted injection in the
intervertebral disc during ESI is not uncommon; it can
be overlooked by those performing the procedure and is
therefore insufficiently reported in the literature.28 This
happens more frequently with TF injections (from
0.17% to over 2%) than with interlaminar procedures
(0.02% to 0.07%).28–31
If the needle is placed in the antero-inferior aspect of
the foramen (ie, closer to the disc), this will probably
increase the chances for intradiscal injection. Despite
optimal placement of the needle, it is possible for
intradiscal spread of contrast fluid to occur; this is due to
the routes that link the epidural space with the
intervertebral disc. This emphasizes the need to use
fluoroscopy to track down this complication.30 Intradis-
cal injection is typically of no consequence, but if
infection occurs, such as spondylodiscitis, this can have
catastrophic results. That is why some experts suggest
the administration of prophylactic antibiotics in higher-
risk patients.28,30
Major Complications. Needle trauma – In 1994, Bog-
duk pointed out that most complications are not related
to the type of corticosteroid that is injected, but more
closely linked to the use of needles or the injection of
substances other than corticosteroids.32 This was later
confirmed in closed medical malpractice claims studies,
in which the majority of complications involved direct
nerve trauma or spinal cord injury.33,34 Temporary
damage to the spinal nerves can occur, especially with
Table 1. Minor Complications Reported after Epidural
Corticosteroid Injections
Type of Complication Frequency
All minor complications 2.4% (per injection)
Accidental disc puncture21 2.3% (lumbar)
Transient exacerbation of pain 1.1%
Accidental dural puncture22 0.33% to 1% (lumbar) and
0.25% to 2.65% (cervical)
Pain at injection 0.33%
Persistent numbness 0.14%
Vasovagal response 0% to 1% (lumbar) and 0.04%
to 8% (cervical)
Benelux Recommendations on ESI  63
lumbar TF injections (4.6%), followed by interlaminar
injections at all levels (0.25% to 0.33%).35 Because
nerve damage can be minimized or avoided altogether if
a patient reports a paresthesia during needle placement
and the procedure is aborted before injection of any
substance within a neural structure itself, the use of deep
sedation is not recommended during these proce-
dures.10,36
Ophthalmological – Retinal venous hemorrhage and
amblyopia were reported after ESIs in volumes over
40 mL. This complication is hypothesized to be sec-
ondary to increased spinal fluid pressure in the sub-
arachnoid space with subsequently raised retinal venous
pressure.37 Transient bilateral vision defects have been
reported after cervical TF application of triamcinolone
15 mg.38 Central serous chorioretinopathy, with
detachment of the central retina, was described in 7
cases and can arise secondarily to fluid retention due to
epidural corticosteroids, with a normal healing process
requiring weeks to months. All these complications are
only described in case reports; thus, the incidence is not
known.10
Neurovascular – Epidural hematoma and ischemia are
examples of potential vascular complications. Most of
the major complications are neurological and are
described further in this article.
Incidence of Major Complications. A department of
the FDA, the Division of Pharmacovigilance II, evalu-
ated serious neurological complications after the epidu-
ral use of corticosteroids via the FDA Adverse Event
Reporting System (FAERS) database. A search was
conducted from January 1, 1965, to April 23, 2014, for
cases of arachnoiditis, and from November 1, 1997, to
April 23, 2014, for cases of serious nervous system
disorders. This yielded a total of 131 cases (including 18
published case reports), which included 41 cases of
arachnoiditis and 90 serious cases of nervous system
disorders.1 Cases of fungal infections due to contami-
nation of the compounded corticosteroid were not
included.
The exact incidence of these major complications
cannot be estimated due to a number of factors:
 Underreporting of complications in the literature.
 The total number of epidural injections per year is
unknown. However, we do know that 1.3 million
epidural injections were given to patients 65 years
of age and older in the United States in 2013.1 IMS
Health data show that approximately 604,000
additional patients under 65 years of age received
an epidural corticoid injection in 2013.2 It is
estimated that the total number of ESIs performed
annually in the United States amounts to 9
million.10
 The low incidence, such that this could never be
reported in retrospective, prospective, or cohort
studies, but only in case reports or in “closed
claims.” A retrospective study involved 4,265
epidural injections (interlaminar, TF, and caudal)
performed on 1,857 patients over a period of
7 years.39 Not a single major complication could
be identified. The number of minor complications
was less after a TF injection (2.1%) than after an
interlaminar injection (6.0%). Various cohort
studies involving a total of over 16,000 consecu-
tive ESIs at all levels also failed to show any major
complications.40–42
Table 2. Information Regarding Injectable Corticosteroids that Are Approved by the U.S. Food and Drug Administra-
tion1
Corticosteroid Tradename Sponsor
Suspension or
Solution Solubility in H2O Notable Excipients
Betamethasone acetate,
betamethasone sodium phosphate
Celestone
Soluspan
Merck Sharpe
Dohme
Suspension Acetate form insoluble;
sodium phosphate
form soluble
Benkalkonium chloride
Dexamethasone sodium phosphate Generic only Multiple Solution Freely soluble Benzyl alcohol
Hydrocortisone sodium succinate Solu-Cortef Pharmacia and
Upjohn (Pfizer)
Powder for
solution
Very soluble
Methylprednisolone acetate Depo-Medrol Pharmacia and
Upjohn (Pfizer)
Suspension Benzyl alcohol
polyethylene glycol
Methylprednisolone sodium succinate Solu-Medrol Pharmacia and
Upjohn (Pfizer)
Powder for
solution
Soluble +/ Benzyl alcohol
Triamcinolone acetonide Kenalog-10
Kenalog-40
Bristol Myers
Squibb
Suspension Benzyl alcohol
Triamcinolone Hexacetonide Aristospan Sandoz Suspension Benzyl alcohol
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In summary, the exact incidence of complications
associated with epidural steroid injections can currently
not be determined, since this requires an extensive
population screening,2 but it is estimated that around 9
million epidural injections are performed annually in the
United States alone. The large number of epidural
injections relative to the number of reports of major
complications justifies the assumption that these are
rare.1,2,39
Neurological Complications and Region. Cervical –
The interlaminar route is predominantly related to
spinal cord injury secondary to needle trauma,34,43
while several case reports describe vascular injury after a
cervical TF approach.34,44–55
Thoracic – The literature on complications in this region
is scarcer,56,57 but procedures in this region are less
frequent, which could explain the lower incidence.
Lumbar – At least 18 cases could be found in the
literature, of which 4 cases had an unclear etiology:
possibly secondary to tumor tissue, hematoma, or
damage to the radicular medullary artery (from the
aorta via arteria lumbalis to arteria spinalis).58–61
Paraplegia after TF injection was reported in 14
cases.62–68 The most frequent nerve root level that led to
complications was L3 (5 cases), followed by L5 (3
cases), L1 and L2 (each 2 cases), and L4 and S1 (each 1
case).
To conclude, complications are most likely to
occur with the interlaminar technique at the cervical
level from direct trauma to the spinal cord and with
the TF technique from a neurovascular complication
(cervical and thoracic more often than lumbar) with
a possibility of an infarction of the spinal cord, the
brain stem, the cerebrum, or the cerebellum.36 There
are multiple hypotheses for this observed damage to
the central nervous system with the TF
technique:
1. Direct damage to the arterial supply of the spinal
cord.54
2. Neurotoxic effect of the injected corticosteroid
and/or preservatives/solvents (“carriers”). The
concentrations of the solvent in the commercially
available preparation makes toxicity unlikely to
occur.69,70
3. Embolization resulting in ischemia after injection
of a corticosteroid suspension.48,53
Although nerve injury due to direct needle trauma
comprises a clear share of the described complica-
tions,33,34 the literature in the past decade has largely
focused on the described complications of accidental
intravascular injection of particulate corticosteroids.
The literature often differentiates between particulate
corticosteroids (as these mixtures contain particles that
are larger than red blood cells) and nonparticulate
corticosteroids (if they contain no particles). That is why
the same terminology will be used in this text. The FDA
does not use this terminology; instead, it differentiates
between 2 chemical categories based on solubility:
specifically, solutions and suspensions. This does not
necessarily coincide with the physical arrangement of
particulate and nonparticulate corticosteroids, but it is
largely comparable.
Data from Medicare and IMS Health up to and
including 2013 show that particulate corticosteroids
make up over 80% of the commercially available
products.2 However, there are also at least 3 cases with
serious neurological complications involving dexam-
ethasone (1 at the cervical and 2 at the lumbar level),1
but it is unclear whether this was in the particulate or
nonparticulate form.
Vascularization. The vascularization of the spinal cord
(Figure 1) usually originates from the aorta via the
radicular artery, arising bilaterally at the level of each
vertebra. The radicular arteries run adjacent to the
segmental spinal nerve in the neuroforamen and provide
vascularization of the nerve, where they also usually
end. However, when these branches continue to the
spinal artery, they are referred to as spinal medullary
arteries (anterior or posterior).
The posterior one-third of the spinal cord is vascu-
larized by 2 posterior spinal arteries. The latter are
relatively small and run posterolaterally along the spinal
cord. They receive their blood supply from the posterior
spinal medullary arteries.
Thus, the greatest vascularization of the spinal cord
(anterior two-thirds) runs through the anterior spinal
artery. This receives cranial arterial blood via branches
of the vertebral artery, at the cervical level by an average
of 3 radicular medullary arteries and below thoracic
level 8, in the majority of cases by 1 single large artery:
the artery of Adamkiewicz (Figure 2). The spinal
medullary artery typically (92% of individuals) runs
anterosuperior to the nerve root71 with an average
intraforaminal diameter of 1.20 mm (0.84 to 1.91 mm).
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This artery is the main blood supply to the conus
medullaris, but the course is unpredictable. Anatomic
studies have shown that the artery of Adamkiewicz
arises, in 75% of cases, from the left posterior inter-
costal artery between T9 and T12 and in 10% of cases
from the lumbar arteries between L1 and L2. A cadaver
study showed the artery of Adamkiewicz between T12
and L3 in 83.9% of the cases. The variability of the
artery of Adamkiewicz was studied based on 4,000
spinal angiograms, which showed that it arises at the
level of L2 in 1% of cases and at the level of L4 in
0.075%.
Directly injecting corticosteroid into the anterior
spinal artery or the artery of Adamkiewicz and the
resultant embolism may lead to an infarction of the
spinal cord. On the other hand, material that is injected
into the abdominal aorta below the level of the artery of
Adamkiewicz may reach the conus via the collaterals.
Normal vascularization can be disrupted by prior
surgery with an increased risk for vascular injury due to
direct damage of the arterial wall. The innermost blood
vessel wall is lined with the tunica intima, which consists
of endothelial cells and subendothelial layers of loose
connective tissue. Direct needle trauma can lead to the
development of an intimal flap that can cause arterial
obstruction.56
Other Complications.
1. Infection due to contamination.72,73 Several
reports of fungal infection after epidural corticos-
teroid administration have been published. These
cases occurred in the United States due to
contamination of methylprednisolone acetate
with the Exserohilum rostratum fungus. The
product was produced in 1 compounding phar-
macy and did not contain preservatives. The
Figure 1. Spinal cord arterial supply. Reproduced with permis-
sion from Neal and Rathmell.229
Figure 2. Blood supply of the spinal cord via the arteria vere-
bralis and radicular medullary arteries. From website anesthesia
key: https://aneskey.com/local-anesthetic-neurotoxicity-and-ca
uda-equina-syndrome/.
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epidural use of this specific preparation led to 753
infections and hundreds of cases of meningitis, at
least 24 of which are known to have resulted in
death.74
2. Two cases of meningitis were possibly attributed
to the activation of latent infections by immuno-
suppression of corticosteroids.37
3. Arachnoiditis. Both epidural and caudal
approaches were associated with a limited num-
ber of cases of arachnoiditis.75,76
4. Subdural injection.22Thesubduralspace is larger in
the cervical region, increasing the risk for subdural
injection. It is important to differentiate between
the signs of subdural and intrathecal block. Respi-
ratory depression occurs slowly (5 to 30 minutes)
with subdural injection; upon direct intrathecal
(subarachnoid) injection, apnea and acute cardio-
vascular collapse occur rapidly (2 to 3 minutes).
In summary, there appear to be more major neuro-
logical complications associated with procedures carried
out at the cervical compared to the lumbar region. This
is likely due to the proximity of a greater number of
vascular structures and the spinal cord itself, which may
be punctured during procedures adjacent to the cervical
spine. Considering this complexity, thorough training of
the pain specialist and use of image guidance is
mandatory before proceeding with cervical procedures.
There is little information on the thoracic region.
Conclusions of the Work Group. Considering the
possible complications, cervical procedures are reserved
for pain specialists with a special competence in inter-
ventional pain therapy.
Is There a Link Between Corticosteroids and/or
Additives and Neurological Complications?
Pharmacokinetics of Corticosteroids1. Chemical clas-
sification of corticosteroids – Corticosteroids are syn-
thetic derivatives of the endogenous hormones from the
adrenal cortex (eg, cortisol, or hydrocortisone in
medicinal form), with several gradations of water
solubility. In general, synthetic corticosteroids are
lipophilic and are supplied as suspensions (eg, triamci-
nolone acetate, triamcinolone hexacetonide, methyl-
prednisolone acetate [MPA], betamethasone acetate). If
corticosteroids are used in the form of a salt structure
(eg, betamethasone sodium phosphate, dexamethasone
sodium phosphate, methylprednisolone sodium
succinate), they are soluble in water and are supplied
as a solution.
Triamcinolone acetate and MPA tend to precipitate
in larger aggregates, but dexamethasone usually does
not contain particles (although they may be present).
Betamethasone is a different case altogether, because the
FDA-approved form has both a soluble (saline) and
nonsoluble (ester) component. Depending on the for-
mulation used, the microscopic analysis of the particle
size differs (Table 2).
It is assumed that the specific formulation of corti-
costeroids can help determine the clinical effect. An ester
formulation, for example, first must undergo hydrolysis
in order to release the active ingredient, causing a longer
onset time but also a longer duration of action.77
It is also possible that additives play a role. However,
there is concern about the potential neurotoxicity with
regard to certain ingredients (eg, benzyl alcohol and
polyethylene glycol [PEG]; see later subsection on
Animal Experimental Data).
Methylprednisolone sodium succinate (Solu-
Medrol) is easily soluble; however, MPA (Depo-
Medrol) is slowly released in a biological matrix and
becomes slowly biologically available. MPA is hydro-
lyzed into its active form by serum cholinesterase.78 In
humans, methylprednisolone demonstrates a weak bond
(40% to 90% bound) with albumin and transcortin. The
intracellular activity of glucocorticoids results in a clear
difference between the plasmahalf-life (2 to 5 hours) and
the pharmacological half-life (12 to over 36 hours). The
pharmacological activity continues after measurable
plasma levels have ceased to be present.79
Dilution and size aggregations – The particles in
corticosteroid suspensions have different sizes and
degrees of aggregation. Methylprednisolone has the
largest particles, triamcinolone is average, and
betamethasone has the smallest particles.48,80,81
Corticosteroids are frequently diluted to reduce the
concentration of benzyl alcohol and PEG prior to the
epidural injection.82,83 The size of particles/aggregates
can also depend upon the dilution agent. For example,
the dilution of methylprednisolone 80 mg/mL with
0.9% NaCl shows an increase in the proportion of
larger particles, contrary to dilution with lidocaine of
compounded betamethasone, which causes the propor-
tion of larger particles to decrease. Dilution with 0.9%
NaCl or lidocaine had no effect on the distribution of
particles in methylprednisolone 40 mg/mL, triamci-
nolone, or commercial betamethasone.81
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Penetration in the cerebrospinal fluid (CSF) – The
penetration of corticosteroids into the CSF depends on
the degree of plasma protein binding and chemical
composition. Animal experiments84 as well as clinical
studies have shown that IV or oral prednisolone can pass
through the blood–brain barrier, with increased values in
the CSF 6 hours after administration.85 The penetration
in the CSF was limited in animal studies by the degree of
protein binding in plasma, whereby a higher free fraction
(ie,notproteinbound)of thecorticosteroid leads tohigher
CSF concentrations. For example, after oral administra-
tionofdexamethasoneorprednisolone inchildren,higher
dexamethasone concentrations are reached in theCSF, as
the dexamethasone is relatively less protein bound than
prednisolone84 after oral administration.
Methylprednisolone succinate (Solu-Medrol) adminis-
tered systemically leads tovery low levels in theCSF.86,87 It is
suspected that thepoorbiologicalavailabilityofmethylpred-
nisolone is due to an active exclusion by P-glycoprotein.86,88
Neurotoxicity in Function of Route of Administra-
tion. Toxicity can arise because of a chemical reaction
of corticosteroid preparations in tissue, or by uninten-
tional intravascular89 or intrathecal injections. Potential
mechanisms leading to neurotoxicity are described in
the ensuing sections.
Chemical irritation due to particles in suspension in
tissue90 – There are indications that in some tissues, such
as lungs and joint prostheses, particles of suspension or
nanoparticles can cause cytokine release, including, for
example, macrophages and neutrophil immigration. The
degree of inflammatory response is conversely propor-
tionate to the particle size and directly proportionate to
the surface area. In suspensions containingMPA, 30% to
40%of the particles have a diameter greater than 20 lm,
while in addition the number of large particles increases
due to aggregation upon dilution. In prosthetic joints, the
critical size of particles to create an inflammatory
response is between 0.2 and 10 lm. This implies that
most corticosteroid particles are too large to cause
serious inflammation, but it is possible that this mech-
anism is nonetheless partially responsible for inflamma-
tory response upon intrathecal administration. Such a
response was not observed at the intrathecal administra-
tion of nonparticulate methylprednisolone succinate.
Intra-arterial – There are various arteries that supply
blood to the spinal cord, as described earlier. Upon
unintentional intravascular injection with corticosteroids,
relatively high corticosteroid concentrations occur in the
spinalcord.Accidentalintra-arterialinjectionofparticulate
corticosteroids can cause clusters or aggregates of the
corticosteroid81 and remotely create an embolus. At the
cervical level, they can thus cause a stroke or spinal cord
infarction; at lumbar levels, infarction of the conus medu-
laris can result in paraparesis or paraplegia. This can result
in serious and permanent limitations, disability, or death.
An animal experimental study69 showed that intra-
arterial injection of the carotis interna can cause significant
brain damage, not only with suspensionMPA (particulate),
but alsowith solutionmethylprednisolone sodiumsuccinate
(nonparticulate corticosteroid) solution as well as the solu-
tion fluid of MPA suspension. The latter was not further
specified. The lesions studied were mainly hemorrhagic. A
studywithEvansbluedye coulddemonstrate adisruptionof
the blood–brain barrier. This animal experimental study
suggeststhatcorticosteroidsolutionscancausedamagetothe
central nervous system not only by means of an embolic
process, but also that the preparation itself and the solution
fluid can have a neurotoxic effect. An additional animal
experimental study showededemaonMRI in theupperpart
of the spinal cord and the brain stem after the injection of
MPA in the carotid arteries of 4 pigs. Injection of dexam-
ethasone (n = 4) andmethylprednisolone sodium succinate
(n = 3) (nonparticulate forms) showed no deviations on
MRI.91 Therefore, the possible toxic effect of methylpred-
nisolone could not be confirmed.
Intrathecal – Clinical. The intrathecal use of corticos-
teroids (such as triamcinolone, MPA) has been described
for 19 different conditions, such as contrast-induced
arachnoiditis after myelography, spasticity in progressive
multiple sclerosis, Guillain-Barre syndrome, failed back
surgery syndrome, post-herpetic neuralgia, amyotrophic
lateral sclerosis, complex regional pain syndrome, and
trigeminal neuralgia.87,90,92,93 Because of reports of serious
complications, particularly after repeated intrathecal injec-
tions,suchascerebralhemorrhage,meningitis,caudaequina
syndrome, progressive muscle weakness, bladder dysfunc-
tion, and paresthesias,37,94 this treatment is no longer used.
Animal experimental data – Animal experimental safety
studies with intrathecal corticosteroids report neuro-
toxicity.95–97 The observed neurotoxicity could also be
caused by the neurotoxic preservatives in the corticos-
teroid preparations used.
In a canine study, MPA was administered after
removing practically all the neurotoxic preservative
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myristyl-gamma-picolinium chloride. Dose-dependent
neurotoxicity was nonetheless observed.95
It remains unclear if the preservatives in corticosteroid
preparations are responsible for the observed neurotox-
icity in humans and animals, but there are indications
that the particles of the corticosteroid suspension and/or
the corticosteroid itself may play
a role in the development of neurotoxicity. The role of
additives and preservatives therefore requires further
investigation. This subject had already been extensively
studied and described by Bogduk in 1994.32
 Buffers: eg, phosphate buffer; no side effects
described after intrathecal or epidural adminis-
tration.
 Polysorbates: no side effects described after
intrathecal injection.
 Citrate: can induce convulsions in mice after
spinal injection.
 Ethylene diamine tetra-acetic acid (EDTA): can
induce convulsions in mice after spinal injection.
 Sodium sulphite: irreversible paralysis in rabbits
after subarachnoid administration.
 Benzalkonium chloride: bacteriostatic preserva-
tive. Celestone chronodose contains benzylalko-
nium chloride and can cause arachnoid fibrosis
after intrathecal injection of over 2 mL in sheep32
and is potentially toxic.37
 Phenol: chemical meningitis has been reported
and can cause convulsions.
Creatinine: Is used as a bulking agent for freeze-
drying. No toxicity reported, but rather a neuroprotec-
tive effect.98
 Polyethylene glycol (PEG): preservative and
increases viscosity with improvement of the sta-
bility of formulation PEG 3% (sometimes added
to methylprednisolone). No inference with neural
function 30 minutes after application at the vagal
nerve of rabbits. PEG >20% can reversibly reduce
the compound action potentials of the A, B, and C
fibers.83 Although there are concerns about the
neurotoxicity of PEG,37 PEG is directly applied to
the myelum in spinal cord injury models to
promote recovery and functional–structural integ-
rity of nerve tissue. It is also clinically used for
dura-recovery, whereby no neurotoxicity or
inflammatory responses were determined. There
is therefore also no proof of direct neurotoxicity
with the intrathecal use of PEG.90
 Benzyl alcohol: preservative effective against
Gram-positive bacteria, and Gram-negative Ser-
ratia marcescens (sometimes present in epidural
abscesses).37 After the intrathecal injection of
benzyl alcohol solutions, the following have been
reported:
○ “flaccid paraplegia” and demyelization with
5 mL benzyl alcohol solution
○ nerve degeneration and paraplegia after 20 mL
methotrexate injection intrathecally with 0.9%
benzyl alcohol
○ “flaccid paralysis”
○ leg paralysis
○ transient neurological problems after the
epidural injection of 40 mL 0.9% NaCl
with 1.5% benzyl alcohol. This resulted in
flaccid paraplegia that continued for
16 months.99 In some countries, methyl-
prednisolone contains 3% PEG and 0.9%
benzyl alcohol.
 Hydroxybenzoates
○ neurological damage, paraplegia
○ neuronal block (paraparesis)
○ neurotoxicity, paraparesis
○ leg paralysis
 Myristyl gamma picolinium chloride: used to
promote the solubility of MPA. Retains the
stability of particulate size and reduces aggrega-
tion and is a preservative that is effective against
Gram-positive bacteria.
○ A safety study in dogs, whereby the neuro-
toxic preservative gamma-picolinium chloride
was virtually entirely removed from the MPA
preparation,95 showed dose-dependent neuro-
toxicity. These finding sheds doubt over the
toxicity of the preservative.
○ A study into the toxicity of MPA on dorsal root
ganglion neurons in rats showed that MPA has
cytotoxic effects. MPA with preservatives (PEG
and Myristyl gamma picolinium chloride)
results in more apoptosis than MPA with
reduced preservatives. MPA with reduced
preservatives results in 12.5% more apoptosis
of neurons than in the control group (normal
saline); however, this difference is not signifi-
cant.70
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Most studies on toxicity used corticosteroids with
preservatives, making it unclear as to specifically indi-
cate which ingredient caused the neurotoxicity.
Epidural Use. When MPA or triamcinolone is injected
into the epidural space, the risk for complications is
small.32,100 The above-mentioned additives, such as
preservatives like alcohol or phenol, or substances that
change solubility such as glycols, were added to these
products, substances that might indeed be toxic if
administered into the epidural space.
The work group under Bogduk in 1994 decided that
there is no evidence of negative effects of corticosteroid
compounds if they are accurately injected into the
epidural space. It is unclear whether a single intrathecal
injection represents a risk for significant injury. The
reported cases of arachnoiditis occurred after repeated
intrathecal injections, and inmost cases in the presence of
pre-existing neurological complaints. Arachnoiditis and
asepticmeningitis are complications of intrathecally, and
not epidurally, administered corticosteroids.21
Conclusion. Neurotoxicity and type of particulate cor-
ticosteroids – The study of the toxicity of particulate
corticosteroids is complicated by the variety in the
composition of the same product from a single manu-
facturer (eg, MPA from Europe vs. MPA from the
United States, a different composition over the course of
time), manufacturing locations (official companies or
industrial pharmacies), and the presence or absence of
preservatives or solvents. The toxicity also depends on
the administration site (epidural, arterial, intrathecal).
Because the composition is usually not specified when
reporting complications, it is very difficult to determine
a causal link between the product and a rare complica-
tion from the literature. The analysis of the FDA FAERS
of serious neurological complications showed that MPA
was involved in 39 of 90 (43%) of the cases, and that
triamcinolone acetate with its smaller particles was
involved in 31 of 90 (34%) of the cases. There are also 3
known cases in which dexamethasone was involved
with serious neurological complications.1
The neurotoxicity of particulate corticosteroids
seems less important when they are injected into the
epidural space, but the composition of the suspen-
sion may play a role in accidental intrathecal or
intravascular injection. Animal experimental data
show that an intrathecal or intravascular injection
can cause complications induced by both the corti-
costeroid as well as the preservatives and/or solvents.
Currently it is not possible to differentiate between
the particulate corticosteroids/suspensions for a bet-
ter safety profile.
Neurotoxicity and additives – The administration of
corticosteroids with as little preservative or solvent as
possible is prompted by fear of intrathecal (with arach-
noiditis) or intravascular injection (neurotoxicity). The
studies of the FDA established 41 cases of arachnoiditis
during a period of almost 50 years (search strategy
between January 1, 1965, and April 23, 2014), usually
after repeated intrathecal injections, and in most cases in
the presence of previously existing neurological com-
plaints. This is not related to the 24 deaths after injection
of fungal-contaminated corticosteroid without preserva-
tives. It is unclear as to what degree the avoidance of
preservatives or solvents can prevent complications after
intravascular injection.
Conclusions of the Work Group.
 The chance for neurotoxicity is small when
glucocorticoids are correctly administered into
the epidural space.
 It is unclear whether the omission of preservatives
and solvents for the prevention of arachnoiditis or
vascular complications outweighs the infection
risk in case of accidental contamination.
 There are currently no indications that any one
type of particulate corticosteroid is safer than any
other.
What Is the Place of Dexamethasone?
Dexamethasone is a solution and therefore a potential
alternative to the epidural injection of particulate
steroids. This section describes the effectiveness and
safety/toxicity of this compound.
Pharmacokinetics.79 Dexamethasone is a synthetic
glucocorticoid, with a strong anti-inflammatory effect
approximately 25 times greater than hydrocortisone
and 7 times greater than prednisolone. Dexametha-
sone has predominantly glucocorticoid activity and
only a very slight effect on sodium and water
retention.
After administration of dexamethasone sodium phos-
phate, it is rapidly hydrolyzed to dexamethasone, which
is 68% bound to plasma proteins.
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After local administration, some absorption into the
systemic circulation is likely. The plasma half-life is
200 minutes for males and 140 minutes for females.
The biological half-life is 35 to 54 hours. There is no
direct link between the plasma concentration and the
therapeutic effect, because a glucocorticoid effect is only
expressed after protein synthesis (including of enzymes)
in sensitive tissue.
Dexamethasone has particles that are either absent or
5 to 10 times smaller than red blood cells (≤0.5 lm) and
does not form aggregates, not even upon dilution with
lidocaine 1% or contrast.48,80 Dexamethasone and
betamethasone sodium phosphate are therefore consid-
ered pure liquids,81 although small particles are also
found in these preparations.48
However, a recent publication demonstrated that the
combination of dexamethasone 1 mL (both 4 mg/mL
and 10 mg/mL concentrations) with 1 mL ropivacaine
0.75% results in almost instantaneous formation of
crystals large enough to act as emboli. Ropivacaine
therefore seems not suitable for the dilution of dexam-
ethasone.101
Safety/Neurotoxicity. In August 2015, we performed a
search over the preceding 5 years using the abstract
words “dexamethasone” AND “epidural” or “intrathe-
cal” and found 376 publications; all abstracts were
screened to establish an inventory of reported side
effects and complications.
Basic research – Intramuscular. The intramuscular
administration of dexamethasone in a spinal cord
compression model resulted in a more rapid neurologic
recovery than in control animals.102
Perineural. The perineural administration of triam-
cinolone hexacetonide, triamcinolone diacetate, or dex-
amethasone considerably reduced the spontaneous
ectopic discharges that arise in experimental nerve end
neuromas. They prevent the further development of
ectopic impulses in freshly severed nerves.103 The
survival of sensory neurons of the spinal ganglion was
studied ex vivo in a study during which they were
exposed to ropivacaine and additives, including dexam-
ethasone, for 2 or 24 hours. After 2-hour exposure, the
association of dexamethasone did not increase
the toxicity of ropivacaine. After 24-hour exposure,
the toxicity of ropivacaine proved far greater than that
of additives, including dexamethasone. However, the
combination of a higher concentration of dexametha-
sone, along with equal doses of ropivacaine, clonidine,
and buprenorphine, did increase toxicity (no toxicity at
66 lg/mL dexamethasone; toxicity at 133 lg/mL). The
authors therefore decided that the concentration effect
of dexamethasone with ropivacaine requires further
study.104 The same group then did an in vivo study
through a single injection or a continuous infusion at the
sciatic nerve of rats with the combination of dexam-
ethasone 66 lg/mL with bupivacaine and clonidine. No
behavioral changes were observed, nor any histopatho-
logical changes at the sciatic nerve, spinal ganglion, or
dorsal/ventral roots. It was concluded that these mix-
tures and concentrations could be safely used on the
sciatic nerve of rats.105
Intra-arterial. Animal experimental studies showed
no neurological complications upon injection of 4 to
10 mg dexamethasone in the vertebral artery of pigs,91
in contrast to particulate corticosteroids.
Epidural. In a formalin pain model, epidural dexam-
ethasone reduced hyperalgesia via an inhibition of
intraspinal phospholipase A2 expression via lamina I
to II in the dorsal horn.106 A dexamethasone gelatine
sponge applied after laminectomy in rats significantly
reduced the occurrence of adhesions and epidural scar
tissue hyperplasia.107
Intrathecal. Intrathecally administered dexametha-
sone weakens glutamate dehydrogenase and glutamate
downregulation, as well as antinociceptive tolerance in
rats in the long term.108 Subdural administration during
1 week of dexamethasone in a rat model of spinal cord
injury resulted in the inhibition of a serious inflamma-
tory response to the damaged myelin.109 In another
study,110 intrathecally administered dexamethasone
worsened thermal hyperalgesia and mechanical allody-
nia in rats with a chronic constriction injury. The
intrathecal administration of a glucocorticoid receptor
antagonist reversed the nociceptive behavior.110,111 The
intrathecal administration of nonparticulate corticos-
teroids in animal experiments resulted in convul-
sions.112–114 In continuous intrathecal administration,
a low dose of dexamethasone resulted in no neu-
ropathology in rats (≤12.5 ng/hour), but a higher dose
(125 ng/hour) did result in inflammation of the lumbar
subarachnoid space.115
Conclusion. Dexamethasone toxicity –
 Perineural injection resulted in increased toxicity
when ropivacaine, clonidine, and buprenorphine
are used together with a high concentration of
dexamethasone (133 lg/mL).
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 Intrathecal administration of higher doses of
dexamethasone (125 ng/hour) resulted in inflam-
mation.
 There is no evidence for toxicity upon intra-
arterial or epidural administration. Upon epidural
administration, inflammation is countered.
Clinical studies – Intrathecal. Glucocorticoids such as
dexamethasone are administered intrathecally to pro-
long the duration of sensory block in spinal anesthesia
and anecdotally for the treatment of various syndromes
like radicular pain, bacterial meningitis, chronic lym-
phocytic leukemia, and nervous involvement in lupus
erythematosus.115,116
Epidural. The epidural use of dexamethasone is
described for the prevention of back pain after epidural
anesthesia,117,118 and for perioperative analgesia during
orchiopexy118 or after cholecystectomy.119
In amonocentric study conducted on 150 patients, the
side effects of dexamethasone (AAP Pharmaceuticals,
10 mg/mL) were prospectively recorded for a 14-day
period after injection of 15 mg cervically or 20 mg
lumbosacrally in the epidural space. This showed that in
19.5% of the cases, side effects were experienced during
the first 30 minutes (numbness and tingling in the limbs
in 11.95%, sometimes followed by perineal pruritus in
4.4% of the cases). Within 3 days, headaches, insomnia,
hiccups, flushing, and increased radicular pain were also
reported. No major complications were registered.120 In
28%, flushing was observed after interlaminar epidural
administration of 16 mg dexamethasone in a retrospec-
tive study. These symptoms mainly occurred in females,
but disappeared within 48 hours.121 The epidural
administration of 15 mg dexamethasone resulted in a
significant drop in serum cortisol and adrenocorti-
cotropic hormone, and of urine cortisol between 2 and
7 days after injection. This normalized after 21 days.122
The FDA received 3 reports of nonfatal serious
neurological adverse events following the epidural use
of dexamethasone. In all cases a new pain in the
extremities was reported, but final neurological outcome
is unknown.1
Conclusion. Safety – Animal experimental data show
that at higher concentrations of dexamethasone, neu-
rotoxicity is present after perineural or intrathecal
injection. The possibility of toxicity produced by the
concurrent administration of local anesthesia does
make it difficult to interpret these data. It is therefore
unclear whether the doses of dexamethasone used
clinically are safe; at present, the FDA has received 3
reports of complications, and recently a conus
medullaris infarction was reported after a TF injection
of 6 mg of dexamethasone at the level of L4.123
In view of the low incidence of neurovascular
complications after TF injections of corticosteroids
and the relatively less frequent use of dexamethasone,
the safety of dexamethasone remains uncertain and can
only be determined by long-term epidemiological studies
and clinical reporting.4
Effectiveness. At the cervical level – The TF adminis-
tration of dexamethasone for cervicobrachialgia was
investigated in 2 retrospective studies124,125 and 1
randomized controlled trial (RCT).126 In 2 studies, a
nonsignificant trend was observed in favor of triamci-
nolone as particulate corticosteroid. The retrospective
study of 2013 with the largest patient group (n = 441)
showed no difference in pain reduction between dex-
amethasone and triamcinolone.124
At the lumbar level – In the first studies at the lumbar
level, the effectiveness of dexamethasone appeared
inferior compared to particulate corticosteroids,127–129
but these were of lower quality (not clearly blinded,
short follow-up period, unclear methodology, under-
powered, or retrospective). Until 2013, there was low-
quality evidence that dexamethasone provided less pain
reduction in comparison with particulate corticos-
teroids.126 Afterwards, the equality of dexamethasone
(10 mg/mL) compared to particulate corticosteroids
was shown in 1 retrospective study (10 mg)130 and 2
RCTs (7.5 and 15 mg).131,132
Conclusion. Effectiveness – Until 2013, there was
evidence that dexamethasone conferred less pain
reduction in comparison to particulate corticosteroids
for cervicobrachialgia and lumbosacral radicular syn-
drome; the 2 largest randomized studies also found
greater effectiveness of particulate corticos-
teroids.129,133
Since then, some studies have indeed been published
that showed an equal effect. However, the latter have
insufficient power and there is currently no direct
evidence that dexamethasone is superior to sham injec-
tions.3 In this conclusion, however, no consideration
was taken of the latest publication132 with 29 and 27
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patients, respectively, in each group (dexamethasone vs.
betamethasone).
Considerations of the Work Group. The place for
dexamethasone – The work group believes that there
are no clear arguments for the interlaminar approach
to choose dexamethasone over particulate corticos-
teroids, in view of the low chance for arachnoiditis or
complications after accidental intravascular injection.
However, in order to rule this out, contrast must
indeed always be used first. The risk for intra-arterial
injection when steroid is applied via an interlaminar
route is negligible owing to the lack of any arterial
structures in normal individuals in the posterior aspect
of the epidural space.
Safety – Clinically there are currently only 4 reports of
serious neurological complications with dexametha-
sone, but the underlying pathophysiology thereof can-
not be determined. The safety of the class of
nonparticulate corticosteroids has still not been suffi-
ciently established, because in 1 animal experimental
study, injection in the carotid artery of methylpred-
nisolone succinate or its carrier also affected the brain.69
The injection of dexamethasone without preservative
did not cause any brain damage, one reason why this
formulation is preferred in practice.
However, the majority of deaths secondary to epidu-
ral steroid injections are due to a single contamination of
preservative-free corticosteroids. The work group there-
fore balances the risk for accidental contamination in
preservative-free dexamethasone on the one hand, and
the risk for an accidental intravascular injection with
neurological complications on the other.
Moreover, in Belgium and the Netherlands the
availability of preservative-free dexamethasone has not
been guaranteed up till now and is only available from 1
compounding pharmacy, making it not feasible to make
its use obligatory as a first-line treatment. This is in
sharp contrast with clinical practice in the United States
and explains the difference in final recommendations
between the U.S. and Benelux guidelines.
It is therefore felt thatbelow the level ofL3 thevascular
risk is smaller, and that particulate steroids still have a
place.
Because the relative safety and effectiveness of
nonparticulate corticosteroids remains an open ques-
tion, the FDA does not make an exception for solutions/
nonparticulate corticosteroids in the warning of the
package leaflet of glucocorticoids.2
Effectiveness – The effectiveness of dexamethasone in
comparison to sham injections has not yet been demon-
strated, and the equality with particulate corticosteroids
was established in studies with insufficient power.
In summary, there is less chance for neurological compli-
cations as a result of accidental intra-arterial or intrathecal
injection with dexamethasone (on the basis of 1 animal
experimental study and only 4 documented serious neuro-
logical complications with dexamethasone). Due to insuffi-
cient clarity about the equivalency of dexamethasone and
safety in the long term, it is notmandatory tousedexametha-
sone. However, the use of particulate corticosteroids is not
advisable for patients with a contrast allergy, and in this
situation dexamethasone is the first choice.
Conclusions of the Work Group.
 Both particulate corticosteroids and dexametha-
sone can be used for lumbar TF injections at level
L3 or lower. Concerning dexamethasone, there
are still insufficient data concerning equivalence
and long-term safety that this cannot be made
obligatory at present.
 There are currently no arguments for switching to
dexamethasone for interlaminarepidural injection.
 In the presence of a contrast allergy or above L3,
dexamethasone should be used transforaminally.
 In patients with an allergy for the contrastmediumor
for corticosteroids, the injection of a local anesthetic
alone can be considered. There is also evidence for the
useofpulsed radiofrequency treatmentadjacent to the
ganglion spinale (dorsal root ganglion).
Effectiveness of Epidural Corticoids. In order to draw
up the risk/benefit balanceof epidural corticosteroids, the
effectiveness of this technique must be reviewed sepa-
rately. There are more than 45 RCTs available that study
the effectiveness of epidural corticosteroids for spine-
related pain, ofwhich 30 are placebo controlled.21,134,135
Despitethisextensiveresearch, thissubjectcontinuestobe
surrounded by much controversy.
Cervical – Four reviews on cervical epidural corticos-
teroids conclude that these are effective in the short
term. Two of these reviews concluded that the interven-
tion is effective in the long-term135–137 and 2 others
found insufficient evidence for effectiveness in the long
term.137–139
Lumbar – There are various systematic reviews and
meta-analyses that have studied the effect of epidural
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corticosteroids on spinal pain. The analyses of effective-
ness, however, were mixed.140–143 Although there is still
substantive criticism,144 the latest reviews usually point
in the same direction: there is proof of moderate to high
quality that epidural corticosteroids have a significant
but clinically limited effect on lumbosacral radicular
pain in comparison with a placebo on leg pain and
function during the first weeks, but this effect disappears
after 3 months.10,21,135,145 There are indications that
surgery can be avoided in 1 study that assessed this as the
primary outcome parameter146 and various studies that
included this as a secondary outcome parameter,147–150
although the latter is inconsistent.151,152
What Is the Place of Epidural Corticoid Injections with
Respect to Subacute Lumbosacral Radicular Pain?
The initial approach to radicular pain is conservative due
to the favorable natural history of this problem (sponta-
neous resolution of pain) or the disappearance of the
complaintswithin 3 months in 75%of the patients.153 In
case of early surgical intervention (6 to 12 weeks after
onsetof thesymptoms),at8 weeks follow-upasignificant
but clinically no longer relevant improvement is achieved
in comparison to a conservatively treated group.154 That
iswhy it is preferable towait 12 weeks before performing
surgery. Between 6 and 12 weeks, there may be consul-
tation with the patient concerning the pros and cons of
conservative vs. surgical intervention, knowing that the
chance for spontaneous recuperation is still present and the
outcome is the same after 1 year. Recovery evolves in the
same way whether a patient with limited motoric drop-out
undergoessurgeryornot.Toallowaninformeddecision,the
potential complications of discectomy should be discussed
with the patient. New or increased neurological drop-out
can occur in 1% to 3%, direct nerve damage in 1% to 2%,
andwoundinfection in1%to2%oftheprocedures.155One
study reported a mortality rate of 0.6 on 1,000 procedures
within 60 days after a lumbar procedure.156
A shared decision is therefore indicated after correct
information is given, since surgery will only mitigate the
acute pain.157,158 In general, a conservative attitude is
recommended in the first phase, depending on the
patient’s preference for rapid pain relief, aversion for
the risks of surgery, and other personal preferences.159
Preferably surgery should only take place after
12 weeks, because then the chance for spontaneous
recovery becomes very small. Patients will require
adequate analgesia during this period, reducing the
radicular irritation and facilitating rehabilitation.152
Due to the limited effects of rest, physical therapy,
paracetamol (acetaminophen), nonsteroidal anti-inflam-
matory drugs, anti-epileptics, or antidepressants,159–161
TF epidural injection with corticosteroids is frequently
carried out. The risk for complications is so low that the
FDA states that the exact incidence cannot be defined for
this procedure, which is frequently performed world-
wide. The efficacy of epidural corticosteroids is pre-
dominantly proven for the short term.
There is also the chance that this treatment canmake it
possible to forego surgery,146,162 although there is still
discussion on the subject.10,145 Carrying out an epidural
steroid injection is cost effective.163 The decision to use
epidural steroids as a stepped-up approach before opting
for surgery is also cost effective164 and has therefore also
been included in the National Institute for Health and
CareExcellence guidelines of theNationalHealth Service
2014.165
Which Route for Administering Epidural Corticoids?
Cervical. The added value of TF administration of
corticosteroids is unclear for cervicobrachialgia.166,167
Although there are theoretical arguments to also opt for
the TF route here, the possible advantage does not
outweigh the described serious neurological complica-
tions when using particulate corticosteroids.21 The use
of dexamethasone has rekindled the discussion on the
ideal approach of epidural corticosteroids, because
complications are also recorded after interlaminar
injection due to a direct needle trauma.
Lumbar. Although not unanimous,168–170 the TF route
is considered superior to the caudal or interlaminar
route in 5 of the 8 comparative RCTs.21 Of the other
studies evaluating the TF approach, 1 was underpow-
ered and 1 indicated a trend toward better results with
the TF route.21
Various technical approaches are possible for the
TF injection. The classic method is done via the safe
triangle; in lateral view, the final point should be
anterior to the neuroforamen (posterior to the vertebra
or the subpedicular position), or alternatively, more
posterior in the neuroforamen (the retroneural posi-
tion) (Figure 3).171,172 Although the final position of
the needle in the cranial part of the neuroforamen can
avoid accidental nerve root trauma and is therefore
promoted as a standard method in textbooks, it does
have the disadvantage that there is a greater chance
to come across a radicular medullary artery at the
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endpoint (Figure 4).71,173 For the purposes of avoiding
a vascular injection at level L3 or above, a more
inferior and posterior approach seems more
appropriate.173
To avoid intra-arterial injection some schools recom-
mend approaching the inferior part of the neuroforamen
(especially for injections above L3), as the artery of
Adamkiewicz rarely traverses this part of the foramen173
The approach is therefore in accordance with the
Kambin triangle174,175 (Figure 5) and is also referred
to as the retrodiscal technique. As the endpoint is
located immediately posterior of the disc, it provides a
higher chance for accidental disc punctures.176 It is also
unclear to which extent a correct epidural contrast flow
can be achieved with this approach.
Consideration of the Work Group. Cervical –
 The work group advises against the TF adminis-
tration of particulate corticosteroids in light of the
lack of proven added value and the potential risks.
A
C
B
Figure 3. Fluoroscopy images of a transforaminal approach of the nerve route L4 left. The blue and brown circles illustrate the
approach via the safe triangle with the final point subpedicular (brown circle and posterior of vertebra) or retro neural (blue circle
and in the dorso-cranial part of the neuroforamen). The pink circle illustrates the Kambin triangle techniquewith an approach lateral of
the superior articular process (SAP) and the final point retrodiscal behind the disc of L4–5.139
Figure 4. Distribution of the intraforaminal location of radicular
medullary arteries at the middle of the pedicle. In 97% of the
cases the artery of Adamkiewicz is located in the upper half of the
neuroforamen.6
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The TF use of dexamethasone is not recom-
mended due to the lack of added value, but it is
currently suspected that dexamethasone is safer in
case of an accidental intra-arterial injection. In the
treatment of subacute cervicobrachialgia with
interlaminar corticosteroid injections, no clear
vascular complications were described with par-
ticulate corticosteroids. Therefore, particulate
corticosteroids and dexamethasone can be used
as of the first injection. In light of the extensive
experience with particulate corticosteroids and
their proven added value in comparison with
control treatment, these are preferred. The corti-
costeroid is usually diluted. This can be done with
0.9% NaCl or lidocaine 1% to 2%.
 Alternatively, a diagnostic root block is recom-
mended for chronic cervicobrachialgia, possibly
followed by a pulsed radiofrequency treatment. In
the event of a short-term or insufficient effect, a
conventional radiofrequency treatment at the
spinal ganglion can be considered.
 Due to the possible complications, cervical pro-
cedures are best performed by algologists with a
special competence in interventional pain therapy.
Lumbar – At the L3 level or lower, the work group
recommends the TF approach in light of the added value
and the lower risk for perforating the artery of
Adamkiewicz. It must be stressed that the vasculariza-
tion is highly variable, with numerous spinal medullary
arterial branches that can be transversing the neural
foramina adjacent to the spinal nerves. The work group
still recommends the approach via the safe triangle, and
for this reason with a clear preference to maintain the
needle tip posterior in the neuroforamen to avoid the
spinal medullary artery. If an intravascular puncture is
detected, it is recommended to move the needle tip to the
posterior middle of the neuroforamen as there is a
smaller chance for encountering blood vessels. Some
researchers propose stopping the procedure after an
accidental arterial puncture as there is a risk that
corticoids will still enter the arterial system after
repositioning.177 However, there is lack of any pub-
lished literature on this subject; moreover, it is not
always possible to distinguish between an arterial or
venous puncture with digital subtraction angiography
(DSA).178
Conclusions of the Work Group. Cervical subacute
cervicobrachialgia –
 Negative recommendation for cervical TF injection
of particulate corticosteroids. Although not recom-
mended, there are currently no counterarguments
for the cervical TF injection of dexamethasone.
 For interlaminar injection, no vascular complica-
tions were reported, and a particulate corticos-
teroid (or dexamethasone 10 mg) can be used. If
required, 0.9% NaCl or lidocaine 1% to 2% can
be used for dilution.
Subacute lumbosacral radicular syndrome –
 The TF approach is recommended via the safe
triangle, with a clear preference to keep the needle
tip placed posterior in the neuroforamen. Particu-
late corticosteroids must only be transforaminally
injected at level L3or lower; this limitation does not
apply for dexamethasone.
Which Dose (Lumbar Level)?
Two RCTs reviewed the dose of epidural corticos-
teroids. In the first study, the interlaminar administra-
tion of 40 to 80 mg methylprednisolone provided the
same result on pain, while the 40-mg group suffered
fewer side effects.179 An 80-mg dose did give patients
with disc extrusion a greater chance to eventually
undergo an operation.180
The second RCT did not show any difference in
effectiveness between the TF administration of 10, 20,
Figure 5. The Kambin triangle, the slanted side of which is
formed by the withdrawing nerve route, the basis for the
underlying vertebra and the side by the processus articularis
superior.146
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or 40 mg triamcinolone.181 The lowest dose of 5 mg did
provide less pain alleviation.
An RCT looked into whether a dose effect of TF
dexamethasone could be determined. There was no
difference in pain or disability 3 months after treatment
between the groups receiving 4, 8, or 12 mg dexametha-
sone.4 The most effective dose in studies that showed a
similarity between dexamethasone and the particulate
corticosteroidsvariedbetween7.5and15 mg.130–132These
studies all used a concentration of 10 mg/mL, after first
having injected a local anesthetic. A prospective study on
the side effects of dexamethasone with 150 patients was
performed also using 10 mg (10 mg/mL concentration).120
Considerations of the Work Group. In view of the
possible physiological side effects, the lack of superiority
of higher doses, and animal experimental data that
indicated a higher chance for neurotoxicity in the event of
accidental intrathecal injection with higher doses, the
work group recommends using the lowest effective dose
of the corticosteroid. Reducing the corticosteroid can
increase the safety of ESI without fully compromising the
pain reduction.182 For triamcinolone this is 10 to 20 mg,
for methylprednisolone 40 mg, and for dexamethasone
10 mg (concentration 10 mg/mL), usually after applica-
tion of a local anesthetic.
Conclusions of the Work Group.
 It is recommended to use the lowest effective dose
of corticosteroids for the epidural injection. This
amounts to 40 mg for MPA, 10 to 20 mg for
triamcinolone acetate, and 10 mg (10 mg/mL) for
dexamethasone phosphate.
Epidural Corticosteroids for Subacute or Chronic Pain?
Althoughevidenceisstill inconsistent,149thereseemstobe
a negative correlation between the duration of existing
complaints and the clinical effectiveness of epidural
corticosteroids.183–187 As a rule, epidural corticosteroids
are thereforebest reserved for radicular pain thathasbeen
continuously present for less than 6 months.
Does the Injected Volume Play a Role?
Cervical. At the cervical level, the optimum volume that
needs to be injected is unknown. Two milliliters of contrast
will spread bilaterally and cranially up to C3, even after an
interlaminarapproach fromC6–7orC7–T1.188Avolumeof
4 mLwill spread epidurally to the level ofC2.43Considering
the narrow epidural margin present at the cervical level
(average 3 mm),189 it is theoretically possible that the
injection of higher volumes in the epidural space can involve
a higher risk for dural puncture.
Lumbar. Thereisasignificantcorrelationofhigherinjected
volumes and better outcome for caudal and lumbar inter-
laminar administration.21,190 This was not determined for
the TF lumbar injections; however, from an anatomical
point of view, a volume of 4 mL in a lumbar TF adminis-
tration reached the superior part of the upper disc aswell as
theinferiorpartoftheunderlyingdiscin93%ofthecases.191
In a studywith dexamethasone, the clinical relevance could
not be determined. The additional rapid administration of
5 mL 0.9%NaCl after a mixture of 4 mg dexamethasone
plus0.33%lidocaine(3-mLsolutions,8 mLintotal)didnot
result inbetter pain relief after4 weeks in comparison to the
dexamethasonemixture of 3 mL.192
Animal experimental193 and clinical data194 often
include the phenomenon of endoneural edema with
secondary ischemia and electromyographic deviations in
the event of traction/pressure on the nerve root. If after
correct positioning of the needle tip an exacerbation still
occurs during epidural injection of local anesthetics and/
or corticosteroids, it is recommended to inject sufficiently
slowly or intermittently. It is possible that this involves a
maximumvolume injectedcervicallyoran ischemiaof the
nerve root secondary to pressure increases. In certain
circumstances, it can be necessary to reduce the volume.
Considerations of the Work Group. There is no scien-
tific added value for injecting large volumes at the
cervical level and for lumbar TF injections. It is
reasonable to recommend a reduction of volumes and
to inject sufficiently slowly for safety reasons.36
Conclusions of the Work Group.
 Limit the cervical interlaminar and (lumbar) TF
volume to 4 mL and inject sufficiently slowly.
Number of Injections?
There is no ideal number of injections; the number of
treatmentsshouldbeindividuallyadjustedinaccordancewith
clinical response.However, consensus has been reached that
additional treatments may only be administered after a 2-
week interval in order to allow proper evaluation and
minimize endocrine side effects.177
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Type of Needle for Transforaminal Injections?
There are different types of needles available that are
expected todecrease the chance for accidental intravascular
injection. A Whitacre (pencil point) needle demonstrated
lower intravascular access (5.4%) than a Quincke needle
(16.2%).195However, this is contrary tootherpublications.
In TF injections, needles with a blunt tip (22 gauge), or
threading up a blunt catheter through a sharp needle (20
gauge) showed a lower incidence of vascular penetration in
comparison with fine needles with a sharp tip (Whitacre
pencil point, 25 gauge). In a comparative study between
these 3 types of needles, therewas significantly less vascular
injection with the blunt catheter (4.9%) that was inserted
throughasharpneedle incomparisonwithblunt-tippedand
sharp-tipped needles (15.6% and 16.5%, respectively).
These results, however, were tempered by the technical
problems thatwere experiencedwith both the blunt catheter
withasharpneedleandneedleswithablunt tip.Needleswith
a blunt tip resulted in additional persistent intravascular
injectionsdespite repositioning,presumablybycausingblunt
trauma in larger foraminal veins, such that probably a route
was created along which the contrast always ran intra-
venously.Theauthors concluded thatnodistinctioncouldbe
made between the different types of needles when it came to
preventing accidental intravascular injections.196
By using needles with extension lines, the number of
unexpected movements of the needle could be kept to a
minimum197 and real-time imaging could be carried out
without the proceduralist’s hands being directly in the
radiation path.
Considerations of the Work Group. There is no needle
whatsoeverwith superior safetywhen it comes topreventing
accidental intravascular injection. The use of needles with
extension lines is, however, recommended.
Conclusions of the Work Group.
 The use of needles with extension lines is recom-
mended for TF injections.
Practical Recommendations for Prevention of
Neurological Complications in the Benelux Union
Fluoroscopy and Contrast in Interlaminar Proce-
dures. Cervical: preventing dural puncture/subdural
injection – At the cervical level, the epidural space at
C6–7 and C7–T1 is the widest, with an average
dimension of 3 mm (1 to 4 mm).189 At C7–T1, in the
dorsal epidural space 1 to 2 mm of fat may be visible on
MRI (rarely more than this), such that this level has
somewhat more margin on interlaminar approach.198
All of this means that interlaminar procedures may
take place preferably at C7–T1, and at the highest at
C6–7, after prior radiological evaluation.198,199 There
are no additional clinical reasons to infiltrate at higher
levels.200,201 Radiological evaluation preferably uses the
MRI to correctly assess the distance between dura and
bone since this is the limiting factor. However, the
minimum distance required for a safe procedure is
unclear.
Fluoroscopy isadditionallyessential since the ligamen-
tum flavum is frequently not fused at the midline at the
cervical level (67% not fused to C6–7, C7–T1), whereby
the loss-of-resistance technique is not reliable to correctly
estimate the depth.202 At the first approach at the cervical
level without fluoroscopy, in 53% of cases a false loss of
resistance is found with incorrect needle placement.201
Fluoroscopy is therefore recommended via a lateral
(profile) image (patient seated, using hanging-drop
technique), whereas others recommend an approach
via a contralateral oblique view22,203 (patient in prone
position with the head positioned on a pillow). How-
ever, the hanging-drop technique in a patient in a seated
position can also incorrectly identify the epidural space,
such that fluoroscopy and contrast administration con-
tinues to be necessary.201,204 The technique with the
patient in the prone position makes it possible to
nonetheless approach the C7–T1 level, despite the
presence of a significant superpositional image due to
broad shoulders. The use of the hanging-drop technique
is not suitable due to the positive cervical pressure in this
position.204,205 There are no data to compare the safety
of these 2 recognized techniques.
Considerations of the Work Group. A prior radiolog-
ical review using MRI (or second choice, CT) is required
to rule out red flags. In addition, it is recommended to
assess the available cervical space,36,206 but it is unclear
what the minimum requirement is for safe administra-
tion of epidural corticoids. If there is limited space
between the dura and the bone, it is recommended to
keep the injection volume and concentration to a mini-
mum, in order to reduce segmental spread and to better
allow neurological evaluation by limiting local anesthet-
ics.36 Because a volume of 4 mL will also reach the higher
cervical segments, and there are no reasons to use greater
volumes, it is reasonable to inject maximally 4 mL.
The work group recognizes the importance of fluo-
roscopy with contrast administration in the execution of
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cervical epidural injections. This can be done using
either a lateral image or an image with an oblique view
(contralateral oblique).
Conclusions of the Work Group.
 Interlaminar cervical level: preferably at C7–T1,
and at the highest at C6–7.
 For cervical epidural injection, prior radiological
review is necessary by MRI (or second choice, CT
scan) to rule out red flags. Additionally, it is
recommended to first assess the available cervical
epidural space.
 Limit the total volume to be injected to maximally
4 mL.
Avoidance of Vascular Injection
Interlaminar Procedures. In a retrospective study, the
vascular pattern of the imaging was studied independently
after an injection of contrast after interlaminar lumbar
injection,TF lumbar injection,or (paramedian) interlaminar
injection at the cervical level. This demonstrated a vascular
pattern in 3%, 8.9%, and 2%, respectively, of the cases.
AlthoughtheTFpath involvesagreaterriskforanaccidental
intravascular injection, this is alsopossible after an interlam-
inar injection.207 Other authors found the incidence of an
intravascular pattern for the TF path at the lumbar level
between 11.2% and 15.5%208,209 and at the cervical level
19.4%.89ThechanceforTFintravascular injectionisgreater
at the S1 level (21.3%) in comparisonwith the lumbar level
(8.1%).208
Considerations of the Work Group. Imaging with
contrast administration for an interlaminar injection is
always needed because a correct positioning of the
needle in the lumbar epidural space with the loss-of-
resistance technique yields many false positive results
(lumbar up to 25%), and for the exclusion of a vascular
puncture (2% at cervical level and 3% at lumbar
level).210–212 No data are available with respect to the
thoracic level.
Conclusions of the Work Group.
 Intheinterlaminartechnique(lumbarandcervical),
fluoroscopy with contrast is required. At the very
least,a lateral image is requiredtoreliablyassess the
depthofneedlepenetration; therearearguments for
carrying out this procedure in a face-downposition
in the interest of better visualization of the contrast
course in an anteroposterior image. There is no
technique (sitting vs. lying down) that has demon-
strated superior safety.
Fluoroscopy and Contrast in Interlaminar Proce-
dures. The administration of contrast is essential for the
exclusion of incorrect positioning of the needle tip89,120:
 Intravenous: the flow can run longitudinally or
transversely, across the center line or to outside
the vertebral canal. If such a pattern is recognized,
it may be sufficient to reposition the needle.
 Intra-arterial: an accidental injection in a radicu-
lar artery (certainly in the artery of Adamkiewicz)
will cause flow medially and cranially at the
midline (anterior spinal artery).
DSA is advised by some,213 but in 1 case an intra-
arterial injection with secondary paraplegia could not
be prevented despite the use of fluoroscopy, 2
sequences of DSA, and a test dose with lidocaine.67
At present, there is insufficient evidence supporting the
use of DSA with ESIs, and DSA does not guarantee a
better clinical outcome or a reduction in complica-
tions.214 It may be considered if the contrast course is
difficult to visualize, for example, if previously admin-
istered contrast is still present, or in the presence of
osteosynthetic material.
Considerations of the Work Group. Contrast adminis-
tration with real-time imaging is essential for the TF
administration of corticoids, since the chance for a
vascular puncture at the lumbar level is between 8% and
15.5% (21.3% at S1) and at the cervical level
19.4%,89,196 with a reasonable chance for crossing the
vertebral artery.215 At the cervical level, it was deter-
mined by CT-fluoroscopy that the needle path in a
cervical TF procedure in 30 out of 70 injections was on
the path of the vertebral artery.215
Because of the possible puncture of the artery of
Adamkiewicz above vertebra L3 and the lack of
added value of the TF epidural administration of
epidural corticosteroids at higher levels, this technique
was only recommended by the work group for root
L3 or lower.
No recommendation can be made concerning DSA,
since it is not clear to what extent this can prevent
intravascular injection, and there is a slightly higher
radiation load on the patient and practitioner.
It is recommended to save images with the final
needle position in the medical record.
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Conclusions of the Work Group.
 WiththeTFtechnique,fluoroscopywithcontrastunder
real-time imaging ismandatory.DSA is optional.
 Despite fluoroscopy with contrast application, an
intravascular injection cannot be fully ruled out.
 The use of a needle with an extension line is
recommended to avoid moving the needle during
the procedure. Despite fluoroscopy contrast
administration/DSA, intravascular injection can-
not be completely ruled out.
Test Dose with Local Anesthetic. In the literature, 1
case is known of a neurological deficit after a cervical TF
injection of contrast and 0.8 mL lidocaine 2%. Symp-
toms occurred 60 seconds after injection of the local
anesthetic. In the subsequent 2 to 3 minutes, the patient
experienced paralysis of all limbs, which completely
disappeared after 20 minutes.53 Based on this case, it
was suggested to use a test dose of local anesthetic before
injecting a corticosteroid.46,214,216 However, this is the
only known case in which it was not clear to what extent
the injection of contrast or lidocaine was responsible for
this effect. In addition, in the above section, a case was
already reported in which fluoroscopy, 2 sequences of
DSA, followed by a test block with lidocaine could not
prevent the occurrence of tetraplegia.217 A retrospective
study on the use of test blocks in cervical TF injections
was able to detect central nervous system symptoms
(after real-time imaging) in 4 of 532 patients (0.75%).
However, it is possible that there were also false-positive
central nervous system symptoms.216
In case of accidental intrathecal injection of local
anesthetic, a motor block can be observed after 3 to
5 minutes.21 Frequently, 1 mL of lidocaine or bupiva-
caine is administered before a TF corticosteroid
injection. In a study in pregnant women, the effective
doses (for 50% and 95% of the sample) of the above
were determined in order to obtain a reliable motor
block after intrathecal injection via an interlaminar
approach.218 This proved for lidocaine 2% to be
13.7 mg (0.69 mL) and 16 mg (0.8 mL), respectively,
and for bupivacaine 0.5% to be 3.4 mg (0.68 mL) and
5.9 mg (1.02 mL), respectively. With 1 mL local anes-
thetic, it is possible to effectively detect a motor block
upon accidental intrathecal injection, but this can only
be done reliably 3 to 5 minutes after injection of a test
dose. The usual tests for this are the Bromage scale and
the hip test, the reliability of which in a patient in the
prone position is not clear. Moreover, the clinical course
of a motor block by an intrathecal injection could
potentially vary for an interlaminar vs. TF approach.
Considerations of the Work Group. Because local
anesthetics decrease pain and have a dilution effect on
potential neurotoxic substances in corticosteroid mix-
tures, it is commonpractice tofirst inject local anesthetics.
It is unclear to what extent a test dose with a local
anesthetic can detect accidental intravascular or intrathe-
cal injection, especially at the lumbar level, because this is
an extrapolation of the cervical level based on 1 case.
Conclusions of the Work Group.
 The injection of a local anesthetic is recommended
prior to a TF corticosteroid injection. Be attentive
to neurological symptoms during the minutes
after an injection. The exact value of these in
detecting accidental intravascular or intrathecal
injection at the lumbar level is not clear.
Avoiding Air. In 1 study, pneumocephalus was
observed after a cervical interlaminar injection, proba-
bly after accidental dural puncture. The patient lost
consciousness 5 minutes after injection of dexametha-
sone 5 mg and ropivacaine, but regained consciousness
after manual ventilation.219
A neurological deficit with blindness occurred in
another case, a few seconds after the TF administration
of 1 mL of air followed by contrast at the cervical level
(after prior accidental puncture of the vertebral
artery).47 The prevention of an air embolus using
0.9% NaCl for the loss-of-resistance interlaminar tech-
nique, or flushing the TF needle and extension line, is
therefore a logical safety measure. Whether this can
really avoid the problem is not known.
Considerations of the Work Group. The avoidance of
unnecessary air in the epidural space is recommended. It
is unclear to what extent the flushing of a puncture
needle with a liquid can prevent pneumocephalus.
Conclusions of the Work Group.
 Preventing unnecessary air in extension lines/
needles by flushing them with a liquid is recom-
mended.
Avoiding Excessive Sedation. In a closed claims anal-
ysis after cervical procedures,34 the most important
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reason was found to be direct needle trauma (31% of the
complications). The impact of anesthesia or sedation on
the procedure is shown by the ratio between patients
with spinal cord trauma who received sedation/anesthe-
sia (67%) compared to patients with complications not
related to the spinal cord (19%) (P < 0.001). Of the
patients who underwent a cervical procedure and
suffered secondary spinal trauma, 25% could no longer
give adequate replies during the procedure, in compar-
ison with only 5% who did not have spinal cord injuries
(P < 0.05).
Considerations of the Work Group. It is the opinion of
the work group that excessive sedation should be
avoided. According to the American Society of Anes-
thesiologists, this is a drug-induced depression of con-
sciousness during which patients cannot be easily
aroused but respond purposefully following repeated
or painful stimulation. It is preferable that a patient be
able to respond adequately during a procedure.36
Conclusions of the Work Group.
 Excessive sedation should be avoided. It is prefer-
able that a patient be able to respond adequately
during a procedure.
Are Prophylactic Antibiotics Needed Upon (Accidental)
Disc Puncture?. As already stated, some experts, and the
most recent guidelines from theUnited Kingdom, suggest
theadministrationofprophylactic antibiotics forpatients
athigherrisk.28,30,220Ontheotherhand, therewasastudy
inwhich200 patientswere followed for at least 3 months
after discography (2-needle technique) without the pro-
phylacticuseofantibiotics.Notasinglecaseofdiscitiswas
reported. In an additional literature search, 10 studies
were found. In 9 studies without the use of prophylactic
antibiotics, an incidence of discitis was reported in 12 of
4,891patients (0.25%).Theonly studywithprophylactic
antibiotics (127 patients) showed no cases of discitis
whatsoever. The authors concluded that, given the low
number of patients in the only study that used prophylactic
antibiotics, and the low incidence of discitis after discogra-
phy, there is not enough evidence to recommend prophy-
lacticantibiotics topreventdiscitis.221Asimilar incidenceof
discitis after discography was found in a systematic review
dealing with cervical discography. Discitis was observed in
21 of 4,804 patients (0.44%). The authors concluded that
the incidence is low and that it may decline further through
the prophylactic use of antibiotics.222
Considerations of the Work Group. The incidence of
discitis after discography is 0.25% to 0.44%. In view of
the seriousness of discitis, prophylactic antibiotics
should be considered in high-risk patients.
Conclusions of the Work Group.
 The routine use of prophylactic antibiotics in disc
puncture is not recommended; however, it may be
considered in high-risk patients.
Sterility. Sterility is essential for the prevention of
major infections such as meningitis and epidural
abscess. Therefore, some guidelines are very strict and
stipulate, in addition to the classic preventive sterility
measures, the use of a sterile surgical gown during all
epidural procedures.220,223 Guidelines related to sterility
during invasive procedures were developed by the Work
Group on Infection Prevention.224
Concern has arisen regarding the possibility that
antiseptics, particularly chlorhexidine/alcohol solutions,
may cause arachnoiditis. However, the causal link is not
clear. Conversely, a retrospective cohort study involving
more than 12,000 patients failed to demonstrate an
increased risk for neuro-axial complications using
chlorhexidine as a skin disinfectant. Moreover, an
in vitro study showed that the use of chlorhexidine in
clinical concentrations was no more cytotoxic than
povidone-iodine, and that possible residual chlorhexi-
dine (if given time to dry) that reached the epidural space
through the needle tip was diluted up to 1:145,000.36
The American Society of Regional Anesthesia and Pain
Medicine work group decided that, based on the
superiority of chlorhexidine as an antiseptic agent, this
is the first choice as disinfectant in the implementation of
neuro-axial procedures.
Conclusions of the Work Group.
 It is advised to follow the guidelines of the Work
Group on Infection Prevention (www.wip.nl).
 Chlorhexidine/alcohol is the first choice for skin
disinfection in neuro-axial procedures. Sufficient
time must be allowed for the skin to dry, and it
should not encounter sterile materials such as
needles, syringes, or medications.
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Anticoagulants. Many complications related to antico-
agulants and epidural infiltrations have been reported.
We refer the reader to recent guidelines regarding this
subject.225
What to Do if You Suspect Neurological Complications
Medullary Ischemia36 and Conus Medullaris Syn-
drome226. If neurological function is not restoredwithin
2 to 3 hours after epidural corticosteroid administra-
tion, anMRI should be performed to rule out medullary
ischemia secondary to an epidural hematoma or abscess;
if negative, this study should be repeated after 24 hours,
since a delayed effect may also be observed. If no direct
access to an MRI is available, an emergency CT scan
should be performed to identify compressive space-
occupying processes that may be eligible for surgical
decompression. This should best be done within 8 to
12 hours after the start of the symptoms to achieve
complete or partial (40% to 66%) neurological recov-
ery. A recent study does cast some doubt on this
conclusion, because in 7 patients, after laminectomy
due to epidural hematoma, no relationship could be
found between the speed of intervention and the neuro-
logical outcome.227 In medicolegal procedures, the early
detection of a neurological complication is stressed.
Often, a neurological deficit is erroneously attributed to
the block with local anesthetic itself, so that time is lost
before the diagnosis is made. The severity of the
neurological deficit at the time of intervention is also a
predictor of the outcome.
If an epidural hematoma or abscess is ruled out, but
medullary ischemia is suspected/confirmed, there are
arguments for maintaining the blood pressure at high-
normal, maintaining normoglycemia, and considering
drainage of CSF. The usefulness of the latter has not been
proven for anesthesia–pain procedure–related spinal cord
ischemia, but it has been demonstrated for surgery-related
spinal cord ischemia. This technique can be considered
since it is safe in case of spinal cord ischemia. The utility of
the use of IV corticosteroids specifically for anesthesia or
pain-related nerve injury is not known. These can be
advantageous in cases of direct spinal cord trauma
through interventional procedures. Conversely, however,
there is an association between a worse neurologic
outcome, directly through corticosteroid-induced neuro-
toxicity and indirectly through hyperglycemia, whereby
corticosteroids are probably best avoided if spinal cord
ischemia is suspected. This can best be discussed with a
neurologist or neurosurgeon consultant.36
Considerations of the Work Group. The work group
recognizes the importance of rapid diagnosis on the
suspicion of nerve injury after epidural injection. This
can be complicated considerably if a high concentra-
tion of a local anesthetic is used, due to the possible
masking of motor block secondary to a severe neuro-
logical cause.
If the procedure is followed by an unexpectedly
prolonged sensory or motor block, the reappearance of
sensory or motor symptoms after an initial disappear-
ance thereof or a nerve block outside the expected
distribution area, treatable causes should be adequately
ruled out. The preferable diagnostic measure is MRI (or
CT if MRI is not immediately available) to rule out
compression by epidural hematoma or abscess. If only
CT is available and this is negative, an MRI should still
be made to rule out spinal cord ischemia.
If no surgically treatable compression is present, and
spinal cord ischemia is suspected, it is advisable to
maintain the blood pressure at high-normal, monitor
glycemia, and consider drainage of CSF.
Conclusions of the Work Group.
 In case of unexpectedly prolonged sensory or
motor block, the reappearance of sensory or
motor symptoms after an initial disappearance
or the occurrence of a nerve block outside the
expected distribution area, an MRI is recom-
mended within 3 hours:
○ MRI negative: new MRI after 24 hours
○ MRI shows epidural hematoma or abscess:
urgent decompression
○ MRI shows spinal cord ischemia: maintain
high-normal blood pressure, normoglycemia,
consider draining CSF
 It is therefore recommended to use short-acting
and low doses of local anesthetics in epidural
mixtures to allow rapid neurological evaluation.
The preference is for lidocaine 1% to 2%.
Arachnoiditis228. Arachnoiditis is a painful condition
caused by inflammation of the arachnoids, one of the
membranes that surround and protect the spinal cord.
The arachnoids may become inflamed by chemical
irritation, bacterial or viral infection, direct injury to
the spinal cord, chronic compression of the spinal
nerves, or complications of spinal surgery or other
invasive spinal procedures. Inflammation can sometimes
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lead to scarring and adhesions, such that the spinal
nerves stick together.
Symptoms – Arachnoiditis can cause several symptoms
such as numbness, tingling, and the characteristic
stabbing and burning in the lower back and legs. Some
people with arachnoiditis may have disabling cramps,
tremors, or spasms. It can interfere with the bladder,
bowel, and sexual function. In severe cases, arachnoidi-
tis can cause paralysis of the legs.
Diagnosis – MRI may show meningeal thickening and
clumping or marginalization of the nerve roots.
Treatment – Arachnoiditis is a disease that is difficult to
treat, and the long-term results are unpredictable. Most
Table 3. Summary of Conclusions
Toxicity and glucocorticoids
• The chances of neurotoxicity are extremely small when the corticosteroids correctly enter the epidural space
• It is still unclear whether leaving out preservatives and solvents for the purposes of preventing arachnoiditis or vascular complications outweighs the
infection risk in the event of accidental contamination
• There are currently no indications that one type of particulate corticosteroid is safer
• It is recommended to inject a local anesthetic prior to a transforaminal corticosteroid injection. Pay attention to any neurological symptoms occurring
within a minute after the injection. The exact value in tracking down an accidental intravascular or intrathecal injection at the lumbar level is unclear
• It is recommended to use the lowest possible dose of a glucocorticosteroid for the epidural injection. Considering effectiveness, this amounts to 40 mg for
methylprednisolone acetate, 10 to 20 mg for triamcinolone acetate, and 10 mg (10 mg/mL) for dexamethasone phosphate
Place of dexamethasone
• In the event of contrast allergy or above the L3 level, transforaminal corticosteroid injections should always be done with dexamethasone.
• Both particulate corticosteroids and dexamethasone are permitted for lumbar transforaminal infiltrations at level L3 or lower. As we currently have too
little information on the long-term safety of dexamethasone and the availability of safe formulations is limited (in the Benelux), this cannot be required
at the moment
• There are currently no arguments in favor of switching to dexamethasone for interlaminar epidural infiltration
Cervical subacute cervico-brachialgia
• Cervical Interlaminar level: preferably at C7–T1, and no higher than C6–7
• A radiological assessment must be performed, including MRI (or CT as a second option) to rule out any red flags before conducting a cervical epidural
infiltration. It is also recommended to assess the available cervical epidural space at the cervical level first
• Negative recommendation for cervical transforaminal injection of particulate corticosteroids. Although not recommended, there are currently no
counterarguments for the cervical transforaminal administration of dexamethasone
• For the interlaminar injection, no vascular complications are reported and a particulate corticosteroid (or dexamethasone 10 mg) can be used. If required,
0.9% NaCl or lidocaine 1% to 2% can be used for dilution
• Limit the total volume to be injected to no more than 4 mL
Place of radiology
• Fluoroscopy with contrast is compulsory for the interlaminar technique at the cervical level and recommended at the lumbar level. At the very least, a
latero-lateral recording must be done; there are arguments to perform this procedure in the prone position as the visualization of the course of the
contrast medium is better in an anteroposterior recording. No superior safety has been determined for any one technique (seated vs. prone)
• With the transforaminal technique, fluoroscopy with contrast under real-time imaging is also compulsory. Digital subtraction angiography is optional
• Despite fluoroscopy with contrast administration/digital subtraction angiography, an accidental intravascular injection cannot be fully ruled out
Lumbar subacute lumbosacral radicular syndrome
• The transforaminal approach is recommended via the “safe triangle,” with a clear preference to keep the needle tip posterior in the neuroforamen.
Particulate corticosteroids may only be transforaminally injected at level L3 or lower; this limitation does not apply for dexamethasone
• After an accidental intrathecal puncture, the needle must be placed in a different location. Once correct epidural positioning has been confirmed, a
glucocorticosteroid may be injected
Epidural volume
• Limit the cervical interlaminar and (lumbar) transforaminal volume to 4 mL (or less if it is too painful) and inject sufficiently slowly
Sterility
• Chlorhexidine/alcohol is the first choice as skin disinfectant for neuro-axial procedures. Allow sufficient time for the skin to dry and avoid contact with
sterile material such as needles, syringes, or medication
What to do in the event of a suspected neurological complication
• In case of unexpectedly prolonged sensory or motor block, the reappearance of sensory or motor symptoms after an initial disappearance or the
occurrence of a nerve block outside the expected distribution area, an MRI is recommended within 3 hours:
s MRI negative: new MRI after 24 hours
s MRI shows epidural hematoma or abscess: urgent decompression
s MRI shows spinal cord ischemia: maintain high-normal blood pressure and normoglycemia, consider drainage of cerebrospinal fluid
• It is therefore recommended to use short-acting and low-dose local anesthetics in epidural mixtures to enable a rapid neurological evaluation. Lidocaine
is therefore preferred
Miscellaneous
• The use of needles with extension lines is recommended for transforaminal injections. It is recommended rinsing with a fluid to avoid any unnecessary air
• Excessive sedation must be avoided. Preferably a patient should be able to respond appropriately during a procedure
• The routine use of prophylactic antibiotics in case of (accidental) disc puncture is not recommended; however, this may be considered for high-risk
patients
• Collaborations: establish agreements with emergency services, the radiology and neurology departments, and back surgeons as to what is to be done in
the event of a suspected neurological complication after epidural corticosteroids
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treatments for arachnoiditis concentrate on pain reduc-
tion and improvement of the symptoms that impede
daily functioning. Combined treatment consisting of
pain management, physical therapy, exercise, and psy-
chotherapy is recommended.
Epidural Abscess: Meningitis36. A spinal epidural
abscess or meningitis may manifest slowly with symp-
toms several days after the procedure, with fever and
back pain, followed by a rapid progression to paralysis.
Rapid diagnosis and treatment is important because
both have a mortality rate of 15%. A rapid diagnosis is
associated with less severe neurological sequelae.
In summary, early detection and appropriate inter-
vention can improve the outcome of patients with
hemorrhagic, infectious, or inflammatory insult. Unfor-
tunately, the same cannot be said of an injury due to
ischemia, anesthetic neurotoxicity, and/or direct
mechanical injury.
CONCLUSIONS
Epidural corticosteroid administration is frequently
performed in pain medicine, predominantly to help the
patient overcome the (sub)-acute phase of radicular
pain. The reports on serious neurological complications
have triggered actions by the FDA and the elaboration of
work groups to define a series of considerations for
improving the safety of the epidural corticosteroid
administration.
The Benelux work group has reviewed the side effects
and complications reported after epidural corticosteroid
administration, and based on the available evidence and
recommendations, including theU.S. safe use recommen-
dation, suggestions are made to improve the safety of
epidural corticosteroid administration. The conclusions
are summarized in Table 3 and the recommendations in
Table 4.
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